March 7, 2019 — Hologic Inc. announced the granting of a CE Mark to the LOCalizer wireless radio frequency identification (RFID) breast lesion localization system. This system is designed for precise and easy marking and targeting of lesions for breast-conserving surgery guidance.
The system is one of many in Hologic’s expanding suite of breast and skeletal health products, including screening, interventional, ultrasound and surgical solutions, that was available for demonstration at the annual European Congress of Radiology (ECR) meeting, Feb. 27-March 3 in Vienna, Austria.
The LOCalizer tag is designed to replace the traditional wire-guided localization method, helping to provide increased comfort and convenience for patients and their healthcare teams. The tag can be implanted up to 30 days prior to a breast-conserving surgery, providing increased flexibility for patients and providers. This improved workflow is designed to help reduce scheduling and logistical hurdles for care teams, and aims to deliver added convenience for an enhanced patient experience. Following placement, the miniature implantable tag can be detected by a portable, handheld reader that indicates the location and distance in millimeters to the lesion, enabling the surgeon to pinpoint the correct area of breast tissue for removal.
Along with the LOCalizer system, Hologic’s newest products in the breast health market include:
-
The SmartCurve breast stabilization system;
-
Clarity HD high-resolution 3-D imaging technology;
-
The Viera portable breast ultrasound system; and
-
The Brevera breast biopsy system with CorLumina imaging technology, which features real-time imaging and sample verification.
Two recent acquisitions of digital specimen radiography company Faxitron Bioptics and Focal Therapeutics, manufacturer of the BioZorb marker, have enabled Hologic to play a larger role in breast-conserving surgery.
Visitors to the Hologic booth at ECR experienced the A.I. Future Suite, where they had a chance to experience current and future applications of artificial intelligence (AI) in breast imaging. In addition, the company’s entire suite of breast and skeletal health products, such as the 3Dimensions Mammography System and Fluoroscan Insight FD Mini C-Arm, were on display and available for demonstration.
Hologic also hosted a variety of workshops during ECR 2019 and a symposium, Advances in Breast Imaging: Clinical use of CEDM across Europe. Workshop topics offered hands-on experience and expert insight into topics including: clinical workflow using tomosynthesis guidance and real-time breast biopsy imaging; a new technique for breast lesion localization; wireless ultrasound guided biopsies; contrast-enhanced mammography in clinical practice; optimization of tomosynthesis reading time; and breast density case reviews.
For more information: www.hologic.com
December 04, 2025 
